Drug Profile

DZD 1516

Alternative Names: DZD-1516

Latest Information Update: 11 Dec 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Dizal Pharmaceutical
Class Antineoplastics
Mechanism of Action ERBB 2 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I HER2 positive breast cancer

Most Recent Events

11 Dec 2023 Phase I development is ongoing in USA and China (Dizal Pharmaceutical pipeline, December 2023)
05 Sep 2022 Efficacy, Adverse events and Pharmacokinetics data from a phase I trial in Breast cancer presented at the European Society for Medical Oncology Annual Meeting (ESMO-2022)
03 Jun 2022 Adverse events and pharmacokinetics data from a phase I trial in Breast cancer presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com